SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company will sponsor a symposium focused on the diagnostic and treatment challenges of Clostridium difficile-associated disease (CDAD), a severe form of hospital-acquired diarrhea, which in the most serious cases can cause death. The symposium will be held on March 31, 2007 at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Munich, Germany.
